Senator Bernie Sanders, I-Vermont, has reintroduced a Medicare for All bill while other Democrats eye an alternative; the Trump administration is appealing a federal judge's decision to toss out Medicaid work requirements in Kentucky and Arkansas; AIDS activists are pushing CDC to force Gilead to give the agency royalties for Truvada.
Senator Bernie Sanders, I-Vermont, who originally introduced his Medicare for All bill in 2016, has reintroduced the legislation, according to Kaiser Health News. While the bill would still create a national single-payer health system with expanded benefits, bar commercial plans from competing with Medicare, and eliminate cost sharing, new revisions to the current bill would also establish a universal provision for long-term care in home and community settings. At the same time, some Democrats are backing a more incremental approach: “Medicare for America” would guarantee universal coverage but leave job-based insurance available for those who want it. The plan would also still require beneficiaries pay some out-of-pocket costs.
Two weeks after a federal judge tossed out Medicaid work requirements in Kentucky and Arkansas, the Trump administration is appealing the ruling, reported the Associated Press. While the Trump administration has argued that work requirements promotes health, US District Judge James Boasberg ruled that the administration’s approval of work requirements implemented numerous obstacles for poor people trying to get healthcare and that federal and state officials failed to evaluate or resolve these challenges adequately.
With increased focused being put on HIV prevention as the country aims toward ending the HIV epidemic, AIDS activists are calling on CDC to reach a deal with Gilead Sciences over its pre-exposure prophylaxis pill, Truvada, which generated $3 billion last year. Activists are arguing that because tax money funded some of the research, CDC should collect royalties from Gilead that could be leveraged to expand access to the pill. According to STAT News, CDC is collecting a small royalty from Mylan for its generic version of the pill, which is sold in Europe, as well as Australia.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen